Acoustic radiation force impulse predicts long-term outcomes in a large-scale cohort: High liver cancer, low comorbidity in hepatitis B virus

Table 4 Cox’s regression analysis for hepatocellular carcinoma occurring after enrollment

	Univariate analysis	Multivariate analysis		95%CI
	P value	P value	Hazard ratio	Lower	Upper
Male	0.005	0.009	20.796	1.293	6.045
Etiology	0.019	0.057
HBV		0.023	40.473	1.232	16.245
HCV		0.150	20.670	0.701	10.173
Age (yr)	< 0.001	0.094	10.028	0.995	1.061
ALT (U/L)	0.188	0.211	0.994	0.985	1.003
AST (U/L)	0.605	0.449	10.005	0.993	1.017
Bilirubin (mg/dL)	0.962	0.326	0.772	0.460	1.295
Platelet (109/L)	< 0.001	0.041	0.993	0.986	1.000
Spleen index (cm2)	0.019	0.169	10.012	0.995	1.030
BMI	0.334	0.524	0.973	0.894	1.059
ARFI (m/s)	< 0.001	0.000	20.775	10.624	4.742
Interferon therapy	0.814	0.943
Pre-enrollment		0.734	0.772	0.174	3.435
Post-enrollment		0.914	0.949	0.366	2.459
Oral anti-virus therapy	0.0174	0.086
Pre-enrollment		0.977	10.031	0.134	7.948
Post-enrollment		0.029	20.105	10.080	4.102
Pre- and post-enrollment		0.110	30.362	0.758	14.903
Hypertension	0.001	0.211	10.554	0.778	3.104
Diabetes mellitus	0.002	0.304	10.460	0.710	3.006
Ischemic stroke	0.305	0.971	00.000	0.000	1.46E+269
Dyslipidemia	0.233	0.065	10.920	0.960	3.840

1274/1749 (72.8%) with complete data, 49 cases (hepatocellular carcinoma). HBV: Hepatitis B; HCV: Hepatitis C; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; BMI: Body mass index; ARFI: Acoustic radiation force impulse.